Every 8-K that Avalo Therapeutics, Inc. (AVTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVTX filings page.
Avalo Therapeutics, Inc. reported second quarter 2026 results and business updates for its IL‑1β‑focused pipeline. The company plans to initiate a registrational Phase 3 program of abdakibart in hidradenitis suppurativa in the first half of 2027 and expects to submit an IND for its next‑generation anti‑IL‑1β antibody AVTX‑010 in the first half of 2027. It also appointed Ron Philip to the board and was added to the Russell 2000 and 3000 Indexes.
Cash, cash equivalents and investments totaled $472.2 million as of June 30, 2026 and are expected to fund operations into 2029. Net cash used in operating activities was $37.7 million for the first half of 2026. Second quarter 2026 research and development expenses were $23.4 million, up $9.3 million year over year, primarily due to a $10.0 million development milestone and other costs for abdakibart in HS. General and administrative expenses were $8.1 million, up $2.9 million, mainly from stock‑based compensation. Net loss was $36.4 million, an increase of $15.6 million year over year, with basic and diluted net loss per share of $0.83 versus $1.92 in the prior‑year quarter.
Avalo Therapeutics appointed Ron Philip to its board of directors effective June 23, 2026. He will serve until the 2027 annual meeting and join the Compensation Committee and the Science, Development and Commercial Advisory Committee.
Under the company’s non-employee director compensation plan, Philip will receive a non-qualified stock option to purchase 40,200 shares of common stock, granted June 23, 2026, vesting in three equal annual installments subject to continued service. The exercise price equals the closing price of Avalo’s stock on that grant date. The board determined he is independent under Nasdaq rules, and he will sign the company’s standard indemnification agreement.
Avalo Therapeutics reported pipeline progress and updated investor materials. The company is advancing AVTX-010, a long-acting next‑generation anti‑IL‑1β antibody, with an Investigational New Drug application planned for the first half of 2027. AVTX-010 is intended for hidradenitis suppurativa (HS) and other inflammatory diseases.
Avalo highlighted abdakibart, its lead anti‑IL‑1β antibody, which produced a 42.5% HiSCR75 response at week 16 in the Phase 2 LOTUS HS trial, versus 25.6% on placebo, and a 61.7% HiSCR50 response versus 40.7%. Safety was described as favorable, with treatment‑emergent adverse event rates similar to placebo.
The investor presentation notes an HS therapeutics market projected above $10B by 2035 and describes Avalo as capitalized to fund operations into 2029, supported by approximately $479M in cash, cash equivalents and investments as of May 31, 2026.
Avalo Therapeutics entered into an exchange agreement with an accredited investor to swap 4,294.675 shares of its Series C preferred stock for 4,294.675 shares of newly created Series C-1 preferred stock. The new Series C-1 is economically similar but removes a restriction so the investor’s beneficial ownership cap can be increased from 4.99% to 9.99% of common stock, subject to a Beneficial Ownership Limitation. After the exchange, 4,085.379 Series C preferred shares remain outstanding.
The company designated the Series C-1 in its charter, with each Series C-1 share initially convertible into 1,000 common shares, featuring no voting rights, parity in dividends and liquidation, and broad-based weighted average anti-dilution protection. Avalo also amended employment agreements for its CEO, CFO, CMO and Chief Business Officer, enhancing severance and change-in-control protections, including up to 18 months of salary for the CEO on certain terminations, cash severance of 1.0x–1.5x salary plus 1.0x target bonus around a change in control, COBRA premium coverage, accelerated equity vesting, and a Section 280G cutback so payments stay just below excise-tax levels if that yields a higher after-tax amount.
Avalo Therapeutics, Inc. held its 2026 annual meeting on June 2, 2026. Stockholders elected seven directors to serve until the 2027 annual meeting. There were 26,714,337 shares outstanding as of the April 6, 2026 record date, with 22,672,284 shares, or about 85%, present or represented by proxy.
Stockholders approved the Second Amended and Restated 2016 Employee Stock Purchase Plan, which had been adopted by the board on April 2, 2026. They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Avalo Therapeutics reported a larger net loss for the first quarter of 2026 while delivering positive clinical and financing milestones. Net loss was $19.6 million, compared with $13.1 million a year earlier, as research and development spending increased to $14.0 million and general and administrative expenses to $6.9 million.
The company ended March 31, 2026 with $82.0 million in cash, cash equivalents and short-term investments, and later completed an underwritten public offering of common stock and pre-funded warrants for gross proceeds of $431.3 million, or approximately $405.0 million net, extending its cash runway into 2029.
Clinically, Avalo reported positive topline Phase 2 LOTUS results for its lead asset abdakibart in moderate to severe hidradenitis suppurativa, meeting the primary endpoint at both doses with around 42% absolute improvement in HiSCR75 response rates at Week 16 versus 25.6% for placebo, and plans to advance into a registrational phase 3 program.
Avalo Therapeutics, Inc. entered into an underwriting agreement to sell 19,730,000 shares of common stock at $17.75 per share and pre-funded warrants to purchase up to 1,400,000 shares at $17.749 per warrant in a public offering. Underwriters also exercised in full a 3,169,500-share option at the public offering price.
The company expects approximately $405.0 million in net proceeds, which, together with its cash, cash equivalents and short-term investments, was estimated at $82.0 million as of March 31, 2026. As of May 4, 2026, 29,326,347 common shares were outstanding.
Avalo plans to use the funds to advance the clinical development of abdakibart, including through its Phase 3 topline data release, and for working capital and general corporate purposes. Based on current plans, it believes this capital will fund operations into 2029.
Avalo Therapeutics reported positive topline Phase 2 LOTUS data for abdakibart (AVTX-009) in moderate to severe hidradenitis suppurativa. The 253‑patient randomized, placebo-controlled trial met its primary endpoint, with HiSCR75 response rates of 42.2% and 42.9% at Week 16 versus 25.6% for placebo.
Key secondary measures, including HiSCR50, International HS Severity Score System (IHS4) and draining tunnel count, were statistically significant or numerically favorable, and responses were similar in patients with and without prior biologic use. Abdakibart was well tolerated, with treatment-emergent adverse event rates comparable to placebo and no neutropenia, serious or opportunistic infections. Avalo plans to advance abdakibart into a registrational Phase 3 program in HS.
Avalo Therapeutics, Inc. entered into a Milestone Buyout Option Agreement and amendment tied to its March 2024 acquisition of AlmataBio, Inc. The original $15 million contingent milestone payment, due upon dosing the first patient in a Phase 3 trial, has been restructured.
Avalo will pay $2.25 million to the former AlmataBio securityholders within five business days of April 26, 2026 and gains an option, exercisable within 90 days, to pay an additional $5.125 million in cash, common stock, or both, in full satisfaction of the milestone. If Avalo does not exercise this option, it would instead owe $12.75 million in cash or stock upon achievement of the Phase 3 dosing milestone.
Avalo Therapeutics, Inc. reported that two members of its board of directors, Dr. Jonathan Goldman and Mitchell Chan, have decided not to stand for re-election at the company’s 2026 Annual Meeting of Stockholders. Both directors will continue serving on the board until that meeting.
The company stated that their decisions are not the result of any disagreement with Avalo on matters related to operations, policies, or practices. The board expressed its appreciation to Dr. Goldman and Mr. Chan for their service and contributions.
Avalo Therapeutics reported 2025 results and highlighted progress on its lead drug abdakibart (AVTX-009). The company expects topline data from its Phase 2 LOTUS trial in hidradenitis suppurativa in the second quarter of 2026, a key milestone for its IL‑1β-based strategy.
Cash, cash equivalents and short-term investments were $98.3 million as of December 31, 2025, which Avalo expects will fund operations into 2028. Research and development expenses rose to $50.1 million and general and administrative expenses to $22.9 million, contributing to a net loss of $78.3 million for 2025.
Avalo Therapeutics, Inc. reported that it estimates having approximately $98 million in cash, cash equivalents and short-term investments as of December 31, 2025, based on figures shared in an updated investor presentation.
The company emphasized that this cash estimate is unaudited, preliminary and does not include full details of its financial condition or results for the year, which will be provided in its future annual report. Avalo also made the updated investor presentation available on its website and attached it as an exhibit to this report for use in meetings with investors.
Avalo Therapeutics (AVTX) reported it issued a press release announcing financial results for the quarter ended September 30, 2025. The company furnished the release as Exhibit 99.1 under Item 2.02, stating it is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as specifically referenced.
The filing lists common stock trading on the Nasdaq Capital Market under AVTX and includes Inline XBRL cover pages as Exhibit 104.
Avalo Therapeutics reported a clinical milestone: it has completed enrollment in its Phase 2 LOTUS Trial evaluating AVTX-009 for hidradenitis suppurativa. The company disclosed the update via a press release furnished as Exhibit 99.1 to this report, dated October 29, 2025. This marks the transition from recruitment to data collection and analysis for the study.
Avalo Therapeutics, Inc. filed a current report to note that on October 10, 2025 it posted an updated investor presentation on its website. This presentation, attached as Exhibit 99.1, is intended for use from time to time in meetings with investors and is incorporated into the report by reference.
The filing does not describe new financial results or major transactions, but formally makes the investor presentation part of Avalo’s public disclosure record for shareholders and analysts who follow the company.
Avalo Therapeutics, Inc. reported the appointment of Taylor Boyd as Chief Business Officer, effective October 1, 2025. Boyd brings nearly 15 years of experience in biotech business development, corporate finance, and investment banking, including senior roles at Abzena and Longboard Pharmaceuticals, where he led significant M&A and licensing activity.
Under an employment agreement dated September 29, 2025, Boyd will receive a base salary of $465,000 and a discretionary annual bonus targeted at up to 40% of base salary, payable in cash or, if mutually agreed, immediately vested equity. As an inducement, he will be granted a stock option for 275,000 shares of Avalo common stock on October 1, 2025, with an exercise price equal to the Nasdaq closing price on the grant date and vesting over four years.
If Avalo terminates Boyd without Cause or he resigns for Good Reason, severance protections include continued salary for nine months (extended to 12 months if termination occurs within six months after a Change in Control), a prorated or enhanced bonus depending on timing, full vesting of outstanding options with six months to exercise, and up to 12 months of COBRA premium payments, all conditioned on a release of claims and compliance with confidentiality, non-disparagement, invention assignment, non-competition, and non-solicitation covenants.
Avalo Therapeutics, Inc. reported changes to its board of directors. The company’s board appointed Kevin Lind as a director effective October 1, 2025, and he will also join the Audit Committee, serving until the 2026 annual meeting or until a successor is elected and qualified.
In line with Avalo’s Amended and Restated Non-Employee Director Compensation Plan, Mr. Lind will receive a non-qualified stock option to purchase 40,200 shares of common stock on October 1, 2025, vesting in three equal annual installments, with an exercise price equal to that day’s Nasdaq Capital Market closing price.
June Almenoff, M.D., Ph.D. resigned as a director, effective October 1, 2025, to pursue new opportunities; her resignation, including from the Audit Committee, is stated as not related to the company’s operations, policies, or practices. Avalo is accelerating vesting of her outstanding equity awards as of October 1, 2025, and extending the expiration dates of her outstanding stock options to September 30, 2026.